Prima Innovations PI-111 topical muscle relaxant

First-In-Class, Patented Topical Muscle Relaxant

Redefining treatment for acute musculoskeletal pain and spasms through a targeted, localized therapeutic approach.

Call (973) 461-9401

Introduction to Prima Innovations LLC

Prima Innovations LLC is a pre-clinical stage pharmaceutical company developing a first-in-class topical muscle relaxant with antispasmodic action designed to target muscle spasms at their source. Prima has established proof-of-principle, based on four different animal models and has established mechanism of action. Headquartered in Wayne, New Jersey, our company is pioneering a localized therapeutic approach for acute musculoskeletal pain relief and chronic muscle spasm conditions. Traditional oral skeletal muscle relaxants often act through the central nervous system (CNS), specifically through sodium channel present in neurons, NaV 1.8; which may lead to systemic side effects such as drowsiness and cognitive impairment. Prima Innovations is developing an alternative — a locally acting proprietary muscle relaxant drug, PI-111, that works specifically through sodium channel present in muscles, NaV 1.4.

Significant Health Issue: Affects 1 in 5 adult Americans. First-in-Class Topical Anti-spasmodic Cream — Our Solution

Why a Localized Muscle Relaxant Matters

Millions of patients worldwide experience muscle spasms associated with acute injury, chronic musculoskeletal disorders, spasticity-related conditions, and mechanical back or neck strain. Prima Innovations is developing a topical skeletal muscle relaxant intended to act directly at the site of spasm.

Direct Delivery

Deliver antispasmodic medication directly to affected muscle groups

Effective Relief

Support quick effective pain relief through localized pharmacologic action, usually within 10 minutes

Differentiated

Provides a unique differentiated mechanism compared to centrally acting agents

Unmet Need

Address an unmet need in muscle spasm treatment

Our investigational compound is being developed to exhibit antispasmodic effect at the muscle level rather than relying primarily on central nervous system modulation. This scientific strategy represents a meaningful advancement in muscle relaxant drug development.

Lead Program

Our Investigational Therapy: A First-in-Class Approach

Prima Innovations' lead program is focused on developing a fast-acting muscle relaxant formulated for topical administration. Unlike over-the-counter drugs like menthol or camphor which are counterirritants or analgesic creams like diclofenac, our therapy is designed as a pharmaceutical-grade antispasmodic medication with a defined mechanism of action at cellular level.

Proof-of-Principle Studies:

  • Rota Rod Study (in vivo)
  • Open Field Test (in vivo)
  • Muscle Twitch Study (in vivo)
  • Isolated Muscle Study (in vitro)

We have also established mechanism of action of PI-111, which is the temporary inhibition of voltage gated NaV 1.4, sodium channel.

PI-111 Anti-Spasmodic Cream

Therapy Application Areas

Neck pain relief

Neck pain relief

Back pain muscle relaxant needs

Back pain muscle relaxant needs

Spasticity treatment medication applications

Spasticity treatment medication applications

Scientific Foundation and Innovation

  • Develops a topical compound for non-CNS muscle relaxation
  • Targets NaV 1.4 sodium channels in skeletal muscle
  • Proof-of-principle validated across multiple animal models
  • Targets a defined patient strategy
Person experiencing neck muscle pain
Doctor holding clinical trial folder

Clinical Development and Growth Strategy

Prima Innovations is preparing to file an Investigational New Drug (IND) application with the FDA. Our development program is structured around rigorous scientific validation at every stage.

  • Formulation studies
  • Toxicology applications
  • Clinical proof-of-efficacy

Prima Innovations is committed to advancing its development program through rigorous scientific validation.

Why Partner with Prima Innovations

Prima represents an opportunity at the intersection of unmet medical need and first-in-class innovation. We are seeking strategic partners and investors to advance our development program.

  • First-in-class topical antispasmodic with defined mechanism of action
  • Proof-of-principle established across four animal models
  • Significant unmet medical need in muscle spasm treatment
  • Pre-clinical stage with clear IND filing pathway
Discuss Partnership

Frequently Asked Questions

Contact Prima Innovations LLC

To learn more about our pre-clinical stage topical muscle relaxant drug or to discuss partnership opportunities, please reach out directly. Prima Innovations welcomes collaboration with investors, research institutions, and strategic pharmaceutical partners committed to advancing innovative muscle spasm solutions.

(973) 461-9401

Redefining Spasm Treatment. Get in Touch.